A Phase 1, Multicenter, Randomized, Controlled, Open-Label, Perioperative Study of AG-120 and AG-881 in Subjects With Recurrent, Non-Enhancing, IDH1 Mutant, Low Grade Glioma
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2018
At a glance
- Drugs AG 881 (Primary) ; Ivosidenib (Primary)
- Indications Glioma
- Focus Biomarker; Pharmacodynamics
- Sponsors Agios Pharmaceuticals
- 13 Mar 2018 Status changed from not yet recruiting to recruiting.
- 14 Feb 2018 According to an Agios Pharmaceuticals media release, first clinical data from this study has been submitted to ASCO.
- 08 Jan 2018 According to a Agios Pharmaceuticals media release, company plans to initiate this trial in first half of 2018.